Elotuzumab, Lenalidomide, and Dexamethasone as Salvage Therapy for Multiple Myeloma
Prior therapy with lenalidomide and shorter disease history were found to correlate with poorer outcomes.
Improved Neurocognitive Function With Hydroxycarbamide in Adolescents With Sickle Cell Disease
Patients who received hydroxycarbamide therapy scored higher on several measures of neurocognition compared to patients who did not receive hydroxycarbamide.
Splanchnic Vein Thrombosis at Presentation of Polycythemia Vera or Essential Thrombocythemia Associated With Increased Mortality
This study investigated differences in the morbidity and mortality of patients presenting with PV or ET with and without splanchnic vein thrombosis.
Do Patients With Cancer Need Disease-Specific Precautions to Prevent COVID-19 Infection?
Although some patients with cancer are at higher risk of developing severe disease should they become infected, these experts suggest the precautions being given to the general population are sufficient — at least for now.
Mucosal Barrier Injuries and Bloodstream Infections Associated With Hematologic Cancer Treatments Reduced With Nurse-Driven Protocol
A 3-cycle Plan-Do-Study-Act intervention resulted in increased nurse and physician education on mucositis and a nurse-driven protocol that reduced MBI-LCBIs by 25%.
Mortality, Complications With Therapeutic Plasma Exchange for Acute Immune TTP
Although 76% of patients reported experiencing complications during treatment, the mortality rate per episode was only 3.7%.
Tailored Approaches to Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Patients with acute myeloid leukemia with myelodysplasia-related changes diagnosed on the basis of dysplasia reported improved overall and event-free survival.
Second Hematologic Malignancy Deemed a “Rare” Event in CLL
The development of a second hematologic malignancy after being diagnosed with chronic lymphocytic leukemia (CLL) appears to be uncommon, a retrospective study found.
Age May Affect Factor VIII Levels in Nonsevere Hemophilia A
Neither factor VIII clotting activity nor factor VIII antigens were significantly different for any blood group in patients with nonsevere hemophilia A.
Ropeginterferon Alfa-2b as a New First-Line Therapy for Polycythemia Vera
In the extension study, 53% of patients receiving ropeginterferon alfa-2b met the primary end points, compared with 38% of patients receiving hydroxyurea.
-
Loading...
-
Loading...
Next post in General Hematology
